FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009832071> ?p ?o ?g. }

• W2009832071 endingPage "962" @default.
• W2009832071 startingPage "951" @default.
• W2009832071 abstract "Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73–1·03; amisulpride 0·66, 0·53–0·78; olanzapine 0·59, 0·53–0·65; risperidone 0·56, 0·50–0·63; paliperidone 0·50, 0·39–0·60; zotepine 0·49, 0·31–0·66; haloperidol 0·45, 0·39–0·51; quetiapine 0·44, 0·35–0·52; aripiprazole 0·43, 0·34–0·52; sertindole 0·39, 0·26–0·52; ziprasidone 0·39, 0·30–0·49; chlorpromazine 0·38, 0·23–0·54; asenapine 0·38, 0·25–0·51; lurasidone 0·33, 0·21–0·45; and iloperidone 0·33, 0·22–0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from −0·09 for the best drug (haloperidol) to −0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to −1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to −0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. Funding None." @default.
• W2009832071 created "2016-06-24" @default.
• W2009832071 creator A5002251483 @default.
• W2009832071 creator A5007077090 @default.
• W2009832071 creator A5017947156 @default.
• W2009832071 creator A5039199295 @default.
• W2009832071 creator A5047242594 @default.
• W2009832071 creator A5052344963 @default.
• W2009832071 creator A5058647332 @default.
• W2009832071 creator A5062056789 @default.
• W2009832071 creator A5068206298 @default.
• W2009832071 creator A5072305202 @default.
• W2009832071 creator A5074939684 @default.
• W2009832071 creator A5086167151 @default.
• W2009832071 creator A5088217633 @default.
• W2009832071 creator A5088839105 @default.
• W2009832071 creator A5091440083 @default.
• W2009832071 date "2013-09-01" @default.
• W2009832071 modified "2023-10-18" @default.
• W2009832071 title "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis" @default.
• W2009832071 cites W1537593241 @default.
• W2009832071 cites W1964162160 @default.
• W2009832071 cites W1970128129 @default.
• W2009832071 cites W1973373637 @default.
• W2009832071 cites W1977083089 @default.
• W2009832071 cites W1995753201 @default.
• W2009832071 cites W2004866510 @default.
• W2009832071 cites W2008257504 @default.
• W2009832071 cites W2010699829 @default.
• W2009832071 cites W2014026290 @default.
• W2009832071 cites W2016880063 @default.
• W2009832071 cites W2020844317 @default.
• W2009832071 cites W2021186654 @default.
• W2009832071 cites W2032902988 @default.
• W2009832071 cites W2039786436 @default.
• W2009832071 cites W2041474698 @default.
• W2009832071 cites W2051386775 @default.
• W2009832071 cites W2075675827 @default.
• W2009832071 cites W2078361138 @default.
• W2009832071 cites W2083674804 @default.
• W2009832071 cites W2093138510 @default.
• W2009832071 cites W2096635847 @default.
• W2009832071 cites W2096883889 @default.
• W2009832071 cites W2098132738 @default.
• W2009832071 cites W2105669432 @default.
• W2009832071 cites W2108344016 @default.
• W2009832071 cites W2109196233 @default.
• W2009832071 cites W2113144077 @default.
• W2009832071 cites W2119971225 @default.
• W2009832071 cites W2121796373 @default.
• W2009832071 cites W2128963487 @default.
• W2009832071 cites W2129132454 @default.
• W2009832071 cites W2129821518 @default.
• W2009832071 cites W2140606211 @default.
• W2009832071 cites W2144625636 @default.
• W2009832071 cites W2149154629 @default.
• W2009832071 cites W2149988964 @default.
• W2009832071 cites W2152770536 @default.
• W2009832071 cites W2157007129 @default.
• W2009832071 cites W2157369969 @default.
• W2009832071 cites W2159155203 @default.
• W2009832071 cites W2165988750 @default.
• W2009832071 cites W2168591853 @default.
• W2009832071 cites W2406978258 @default.
• W2009832071 cites W3022903699 @default.
• W2009832071 cites W4211084476 @default.
• W2009832071 cites W4211193412 @default.
• W2009832071 cites W4211202241 @default.
• W2009832071 cites W4211261106 @default.
• W2009832071 doi "https://doi.org/10.1016/s0140-6736(13)60733-3" @default.
• W2009832071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23810019" @default.
• W2009832071 hasPublicationYear "2013" @default.
• W2009832071 type Work @default.
• W2009832071 sameAs 2009832071 @default.
• W2009832071 citedByCount "1962" @default.
• W2009832071 countsByYear W20098320712013 @default.
• W2009832071 countsByYear W20098320712014 @default.
• W2009832071 countsByYear W20098320712015 @default.
• W2009832071 countsByYear W20098320712016 @default.
• W2009832071 countsByYear W20098320712017 @default.
• W2009832071 countsByYear W20098320712018 @default.
• W2009832071 countsByYear W20098320712019 @default.
• W2009832071 countsByYear W20098320712020 @default.
• W2009832071 countsByYear W20098320712021 @default.
• W2009832071 countsByYear W20098320712022 @default.
• W2009832071 countsByYear W20098320712023 @default.
• W2009832071 crossrefType "journal-article" @default.
• W2009832071 hasAuthorship W2009832071A5002251483 @default.
• W2009832071 hasAuthorship W2009832071A5007077090 @default.
• W2009832071 hasAuthorship W2009832071A5017947156 @default.
• W2009832071 hasAuthorship W2009832071A5039199295 @default.
• W2009832071 hasAuthorship W2009832071A5047242594 @default.
• W2009832071 hasAuthorship W2009832071A5052344963 @default.
• W2009832071 hasAuthorship W2009832071A5058647332 @default.
• W2009832071 hasAuthorship W2009832071A5062056789 @default.
• W2009832071 hasAuthorship W2009832071A5068206298 @default.
• W2009832071 hasAuthorship W2009832071A5072305202 @default.
• W2009832071 hasAuthorship W2009832071A5074939684 @default.

• next